PMID- 16979125
OWN - NLM
STAT- MEDLINE
DCOM- 20061213
LR  - 20131121
IS  - 1567-5769 (Print)
IS  - 1567-5769 (Linking)
VI  - 6
IP  - 11
DP  - 2006 Nov
TI  - 5-androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with 
      radiation-induced myelosuppression.
PG  - 1706-13
AB  - Total body ionizing irradiation (TBI) between 2-8 Gy causes the hematopoietic 
      component of the acute radiation syndrome (ARS) in humans. Here we report on an 
      exploratory study with 5-androstenediol (AED) in rhesus monkeys exposed to 4 Gy 
      (60)Co gamma TBI. In this study, the effects of two formulations administered 3-4 
      h after irradiation were evaluated. After radiation, severe neutropenia (<500 
      neutrophils/microL), thrombocytopenia (<50,000 platelets/microL), and anemia 
      (hemoglobin <8.0 g/dL) occurred in 6, 6, and 5 of the 6 control animals, 
      respectively. In these 6 control animals, the median time to first day of each 
      defined cytopenia was 8.5, 13, and 20 days and the median time to last occurrence 
      was 22.5, 19.5 and 29.5 days, respectively. All treated groups had a decrease in 
      the duration of severe neutropenia relative to vehicle control. All but one 
      dosing regimen decreased the duration of thrombocytopenia and anemia. Five 
      consecutive days of a 15 mg/kg intramuscular (IM) micro-particle preparation and 
      a once weekly 15 mg/kg subcutaneous (SC) nanoparticle suspension generally 
      provided the greatest radiation protection. AED, as a single agent, promotes 
      multilineage hematopoietic recovery of the bone marrow. These data suggest that 
      it may play an important therapeutic role in the management of acute radiation 
      syndrome.
FAU - Stickney, Dwight R
AU  - Stickney DR
AD  - Hollis-Eden Pharmaceuticals, Inc., 4435 Eastgate Mall, Suite 400, San Diego, CA 
      92121, USA. dstickney@holliseden.com <dstickney@holliseden.com>
FAU - Dowding, Charles
AU  - Dowding C
FAU - Garsd, Armando
AU  - Garsd A
FAU - Ahlem, Clarence
AU  - Ahlem C
FAU - Whitnall, Mark
AU  - Whitnall M
FAU - McKeon, Marie
AU  - McKeon M
FAU - Reading, Christopher
AU  - Reading C
FAU - Frincke, James
AU  - Frincke J
LA  - eng
PT  - Journal Article
DEP - 20060728
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 95PS51EMXY (Androstenediol)
SB  - IM
MH  - Androstenediol/*pharmacology
MH  - Anemia/drug therapy
MH  - Animals
MH  - Female
MH  - Hematopoiesis/*drug effects
MH  - Macaca mulatta
MH  - Male
MH  - Neutropenia/drug therapy
MH  - Particle Size
MH  - Radiation Injuries, Experimental/*drug therapy
MH  - Thrombocytopenia/drug therapy
MH  - Whole-Body Irradiation/*adverse effects
EDAT- 2006/09/19 09:00
MHDA- 2006/12/14 09:00
CRDT- 2006/09/19 09:00
PHST- 2006/04/11 00:00 [received]
PHST- 2006/06/22 00:00 [revised]
PHST- 2006/07/06 00:00 [accepted]
PHST- 2006/09/19 09:00 [pubmed]
PHST- 2006/12/14 09:00 [medline]
PHST- 2006/09/19 09:00 [entrez]
AID - S1567-5769(06)00205-0 [pii]
AID - 10.1016/j.intimp.2006.07.005 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2006 Nov;6(11):1706-13. doi: 10.1016/j.intimp.2006.07.005. 
      Epub 2006 Jul 28.